EF
CTMX icon

Empowered Funds’s CytomX Therapeutics CTMX Stock Holding History

Empowered Funds’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,332
Closed -$133K – 2124
2025
Q4 		$133K Buy
+31,332
New +$119K ﹤0.01% 961

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Empowered Funds's CTMX Position: Q1 2026 in Review

Empowered Funds sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 31,332 shares — an estimated $133K sold.

Empowered Funds first reported a position in CTMX in Q4 2025 and held it in 1 quarter. The position peaked at $133K in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Empowered Funds reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Empowered Funds sold 31,332 CytomX Therapeutics shares in Q1 2026, an estimated $133K.
  • Empowered Funds first reported a position in CytomX Therapeutics in Q4 2025 and held it in 1 quarter.
  • Empowered Funds's CytomX Therapeutics position peaked at $133K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.